Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04498117 · ClinicalTrials.gov registry record · Phase 3
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
A Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, sponsored by CanariaBio.
- Active
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
- 20
- Study locations
NCT04498117 is a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms that is active but no longer recruiting, run by CanariaBio. The registered enrollment target is 615 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT04498117, a Phase 3 study of Ovarian Cancer and Ovarian Neoplasms, is active but no longer recruiting, sponsored by CanariaBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Placebo
- BIOLOGICAL Oregovomab
Study Locations (20)
California
- John Muir Health Clinical Research Center - Concord
- Kaiser Permanente Southern California - Irvine
- Moores UC San Diego Cancer Center - La Jolla
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Epic Care - Pleasant Hill
- Kaiser Permanente Riverside Medical Center - Riverside
- University of California, Davis Comprehensive Cancer Center - Sacramento
- Contra Costa Oncology - Walnut Creek
- John Muir Health Gynecologic Cancer Services - Walnut Creek
Connecticut
- University of Connecticut Health Center - Farmington
- Smilow Cancer Hospital - New Haven
- Yale University School of Medicine - New Haven
Arizona
- Honor Health - Phoenix
- The University of Arizona Cancer Center - Tucson
Florida
- AdventHealth Orlando - Orlando
- Women's Cancer Florida/Women's Cancer Associates - St. Petersburg
Hawaii
- The Queens Medical Center - Honolulu
- Kapiolani Medical Center for Women and Children/University of Hawaii - Honolulu
Colorado
- University of Colorado Health - Aurora
Georgia
- Lewis Cancer & Research Pavilion at St. Joseph's Candler - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2028-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04498117
The ClinicalTrials.gov registry entry for NCT04498117 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 615 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (15% lower). The listed sponsor is CanariaBio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04498117 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT04498117 about?
NCT04498117 is a clinical study titled "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery". Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal deb...
What is the current status of trial NCT04498117?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 615 participants. The study started on 2020-08-25. Estimated completion is 2028-08-26.
What conditions does trial NCT04498117 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms.
What interventions are being tested in trial NCT04498117?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Placebo (BIOLOGICAL), Oregovomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04498117?
This trial is sponsored by CanariaBio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04498117 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.